A serum-soluble factor(s) stimulates tumor growth following laparotomy in a murine modelrid=""id=""Presented at the annual meeting of the Society of American Gastrointestinal Endoscopic Surgeons (SAGES), San Antonio, TX, 26 March 1999

Lee, S. W.; Gleason, N. R.; Southall, John; Allendorf, John D.; Blanco, I.; Huang, Emina H.; Bessler, Marc; Whelan, Richard L.

doi:10.1007/s004640020061

Cited by 28 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extensive clinical and experimental evidence indicates that tumor removal adversely alters the growth kinetics of residual neoplasia (11)(12)(13)(14)(15)(16)(17)(18). Tumor cell proliferation is increased in local tumor recurrences following curative-intent excisional surgery (3,7).…”

mentioning

confidence: 99%

Phosphoinositide 3-Kinase Accelerates Postoperative Tumor Growth by Inhibiting Apoptosis and Enhancing Resistance to Chemotherapy-induced Apoptosis

Coffey¹,

Wang²,

Smith³

et al. 2005

Journal of Biological Chemistry

View full text Add to dashboard Cite

Tumor removal remains the principal treatment modality in the management of solid tumors. The process of tumor removal may potentiate the resurgent growth of residual neoplastic tissue. Herein, we describe a novel murine model in which flank tumor cytoreduction is followed by accelerated local tumor recurrence. This model held for primary and recurrent tumors generated using a panel of human and murine (LS174T, DU145, SW480, SW640, and 3LL) cell lines and replicated accelerated tumor growth following excisional surgery. In investigating this further, epithelial cells were purified from LS174T primary and corresponding recurrent tumors for comparison. Baseline as well as tumor necrosis factor apoptosis-inducing ligand (TRAIL)-induced apoptosis were significantly reduced in recurrent tumor epithelia. Primary and recurrent tumor gene expression profiles were then compared. This identified an increase and reduction in the expression of p110␥ and p85␣ class Ia phosphoinositide 3-kinase (PI3K) subunits in recurrent tumor epithelia. These changes were further confirmed at the protein level. The targeting of PI3K ex vivo, using LY294002, restored sensitivity to TRAIL in recurrent tumor epithelia. In vivo, adjuvant LY294002 prolonged survival and significantly attenuated recurrent tumor growth by greatly enhancing apoptosis levels. Hence, PI3K plays a role in generating the antiapoptotic and chemoresistant phenotype associated with accelerated local tumor recurrence.

show abstract